$0.05 0.0 0.0%
Last Trade - 15/04/21
| Market Cap | £106.6m |
| Enterprise Value | £110.4m |
| Revenue | £51.4m |
| Position in Universe | th / 6851 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.3 | 36.2 | 56.9 | 73.8 | 56.5 | 72.7 | +31.7% | ||||
| +124.5 | +101.1 | +28.9 | +36.0 | +8.0 | ||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.
| Last Annual | December 31st, 2010 |
| Last Interim | September 30th, 2011 |
| Incorporated | January 28, 2004 |
| Public Since | May 15, 2012 |
| No. of Shareholders: | 58 |
| No. of Employees: | 233 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 2,944,515,543 |
| Free Float | (0.0%) |
| Eligible for |
×
ISAs
✓
SIPPs
|
| Address | 16 Cheng Zhuang Road Feng Tai District, BEIJING, 100071, China |
| Web | http://www.lotuspharma.com |
| Phone | +86 10 63899868 |
| Contact | () |
| Auditors | Friedman LLP |
As of 15/04/21, shares in Lotus Pharmaceuticals Inc are trading at $0.05, giving the company a market capitalisation of £106.6m. This share price information is delayed by 15 minutes.
Shares in Lotus Pharmaceuticals Inc are currently trading at $0.05 and the price has moved by 0.354k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lotus Pharmaceuticals Inc price has moved by 0.200k% over the past year.
There are no analysts currently covering Lotus Pharmaceuticals Inc.
Lotus Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Lotus Pharmaceuticals Inc does not currently pay a dividend.
Lotus Pharmaceuticals Inc does not currently pay a dividend.
Lotus Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Lotus Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Lotus Pharmaceuticals Inc are currently trading at $0.05, giving the company a market capitalisation of £106.6m.
Here are the trading details for Lotus Pharmaceuticals Inc:
We were not able to load our ranking data for Lotus Pharmaceuticals Inc
We were not able to load any forecast data for Lotus Pharmaceuticals Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 0.311k%. At the current price of $0.05, shares in Lotus Pharmaceuticals Inc are trading at 67.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lotus Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 0.23. The shares are currently trading at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lotus Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Lotus Pharmaceuticals Inc based on the size of their shareholding:
